首页> 美国卫生研究院文献>Frontiers in Immunology >Composite Tissue Allotransplantation and Dysregulation in Tissue Repair and Regeneration: A Role for Mesenchymal Stem Cells
【2h】

Composite Tissue Allotransplantation and Dysregulation in Tissue Repair and Regeneration: A Role for Mesenchymal Stem Cells

机译:复合组织同种异体移植和失调在组织修复和再生:间充质干细胞的作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Vascularized composite tissue allotransplantation is a rapidly evolving area that has brought technological advances to the forefront of plastic surgery, hand surgery, and transplant biology. Composite tissue allografts (CTAs) may have profound functional, esthetic, and psychological benefits, but carry with them the risks of life-long immunosuppression and the inadequate abilities to monitor and prevent rejection. Allografts may suffer from additional insults further weakening their overall benefits. Changes in local blood flow, lack of fully restored neurologic function, infection, inflammation with subsequent dysregulated regenerative activity, and paucity of appropriate growth factors may all be involved in reducing the potential of CTAs and therefore serve as new therapeutic targets to improve outcomes. Strategies involving minimized immunosuppression and pro-regenerative therapy may provide a greater path to optimizing long-term CTA function. One such strategy may include mesenchymal stem cells (MSCs), which can provide unique anti-inflammatory and pro-regenerative effects. Insights gained from new studies with MSCs on composite allografts, advances in tissue regeneration reported in other MSC-based clinical studies, as well as consideration of newly described capacities of MSCs, may provide new regenerative based strategies for the care of CTAs.
机译:血管化复合组织同种异体移植是一个快速发展的领域,已将技术进步带到了整形外科,手外科和移植生物学的前沿。复合组织同种异体移植(CTA)可能具有深远的功能,美学和心理益处,但伴随着它们存在终身免疫抑制的风险以及监测和预防排斥反应的能力不足。同种异体移植可能会遭受额外的侮辱,从而进一步削弱其整体利益。局部血流的变化,缺乏完全恢复的神经功能,感染,炎症以及随后的再生活性失调以及缺乏适当的生长因子都可能与降低CTAs的潜力有关,因此可作为改善治疗效果的新治疗靶点。涉及最小化免疫抑制和促再生疗法的策略可能为优化长期CTA功能提供更大的途径。一种这样的策略可以包括间充质干细胞(MSC),其可以提供独特的抗炎和促再生作用。 MSC对复合同种异体移植物的新研究获得的见解,其他基于MSC的临床研究中报道的组织再生方面的进展以及对MSC的新描述能力的考虑,都可能为CTAs的治疗提供基于再生的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号